Home / Search / Multiple Sclerosis (MS)

Multiple Sclerosis (MS)

Autoimmune demyelinating disease affecting 2.8M people worldwide. Most advanced of the major neurodegenerative diseases in treatment options. Remyelination represents the next major research frontier beyond immunomodulation.

Search Multiple Sclerosis (MS) evidence →
1,923
Papers (5yr)
12
Active trials
3
Tracked biomarkers
3
Related diseases
Research signals

SM-452 remyelination therapy completed Phase II with 61% lesion reduction. Phase III fully enrolled, historical pattern score High (79%) based on analogous completed trials. View full research signals ->

Tracked biomarkers
NfL (CSF/blood)Strong evidence

Tracks disease activity and treatment response. Widely validated across MS trial programs.

IL-6/TNF-aModerate evidence

Neuroinflammatory panel shared with ALS research, cross-validation opportunity identified.

OCT (retinal imaging)Moderate evidence

Non-invasive imaging biomarker for neurodegeneration in MS.

Active clinical trials
NCT IDDrugPhaseStatusSponsor
NCT05432108SM-452 remyelination therapyPhase IIIActiveGenentech

View all ALS trials in platform →

Related diseases — shared mechanisms

Phase 1 primary cohort + monitored diseases

ALS
Shared: neuroinflammation biomarkers
Alzheimer's
Shared: neuroinflammation
Parkinson's
Shared: microglial activation
Research and educational use only. Information does not constitute medical advice, diagnosis, or treatment recommendations. Verify with primary literature. AI disclaimer →